Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (31-40 of 372) with videos related to

Pageof 38
Sort By:
American Journal of Hematology|June 25, 2016
Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugsEmilie Chalayer, Céline Chapelle, Xavier Leleu, et al.
Leukemia|April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myelomaXavier Leleu, Arthur Bobin, Andre Herbelin, et al.
The Lancet. Oncology|February 5, 2026
Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' replySalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Blood|August 20, 2002
Efficacy of a low dose of thalidomide in advanced multiple myelomaXavier Leleu, Leonardo Magro, Abir Fawaz, et al.
European Radiology|March 21, 2013
Low-dose biplanar skeletal survey versus digital skeletal survey in multiple myelomaNathalie Boutry, Bastien Dutouquet, Xavier Leleu, et al.
Expert Review of Hematology|September 21, 2021
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weeklyXavier Leleu, Ajai Chari, Shambavi Richard, et al.
Leukemia & Lymphoma|June 28, 2021
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myelomaDavid Siegel, Katja Weisel, Anita Zahlten-Kumeli, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2023
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide ExposureFaith E Davies, Xavier Leleu, Prisca Vogel, et al.
Med (New York, N.Y.)|June 12, 2026
Five trials reshaping multiple myelomaAlexis Talbot, Arthur Bobin, Cyrille Touzeau, et al.
European Journal of Haematology|March 24, 2009
Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patientsGhandi Damaj, Frédérique Kuhnowski, Jean-Pierre Marolleau, et al.
Pageof 38

Showing results (31-40 of 372) with videos related to

Sort By:
Pageof 38
American Journal of Hematology|June 25, 2016
Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugsEmilie Chalayer, Céline Chapelle, Xavier Leleu, et al.
Leukemia|April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myelomaXavier Leleu, Arthur Bobin, Andre Herbelin, et al.
The Lancet. Oncology|February 5, 2026
Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' replySalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Blood|August 20, 2002
Efficacy of a low dose of thalidomide in advanced multiple myelomaXavier Leleu, Leonardo Magro, Abir Fawaz, et al.
European Radiology|March 21, 2013
Low-dose biplanar skeletal survey versus digital skeletal survey in multiple myelomaNathalie Boutry, Bastien Dutouquet, Xavier Leleu, et al.
Expert Review of Hematology|September 21, 2021
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weeklyXavier Leleu, Ajai Chari, Shambavi Richard, et al.
Leukemia & Lymphoma|June 28, 2021
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myelomaDavid Siegel, Katja Weisel, Anita Zahlten-Kumeli, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2023
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide ExposureFaith E Davies, Xavier Leleu, Prisca Vogel, et al.
Med (New York, N.Y.)|June 12, 2026
Five trials reshaping multiple myelomaAlexis Talbot, Arthur Bobin, Cyrille Touzeau, et al.
European Journal of Haematology|March 24, 2009
Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patientsGhandi Damaj, Frédérique Kuhnowski, Jean-Pierre Marolleau, et al.
Pageof 38